SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), a biopharmaceutical company, is focused on developing and commercializing innovative therapeutics designed to treat life-threatening diseases. The company’s strategy is to in-license late-stage clinical products, and then develop them for commercialization throughout the world. SciClone simultaneously strives to increase revenues and important cash flow to fund the expansion of its business as well as the development of a worldwide product portfolio. For further information, visit the Company’s web site at www.sciclone.com.
- 16 years ago
QualityStocks
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Nightfood Holdings Inc. (NGTF) Leading Hospitality Tech Revolution with Innovative Solutions
Nightfood Holdings (OTCQB: NGTF) is modernizing the hospitality industry with its AI-driven robotics solutions and innovative…
-
QualityStocksNewsBreaks – SolarBank Corp.’s (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Vision in Action: Building the Grid of Tomorrow
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a…
-
QualityStocksNewsBreaks – ROTH Conference Marks a Quarter-Century of Community in Dana Point
The 37th Annual ROTH Conference drew thousands of participants from around the globe to Dana…